Opus Genetics (IRD) Director Cam Gallagher Exercises 784,314 Warrants

What Happened

• Cam Gallagher, a director of Opus Genetics, exercised warrants (transaction code M) on Sept 8, 2026 to acquire 784,314 shares of common stock at $1.15 per share, for a cash outlay of $901,961. The filing also reports the corresponding disposition of the derivative (the warrant) at $0, reflecting conversion into the underlying shares.

Key Details

• Date of transaction: 2026-09-08.
• Acquired: 784,314 common shares at $1.15 each; total paid ~$901,961.
• Disposed: 784,314 derivative units (the warrants) reported at $0 (converted into shares).
• Shares owned after the transaction: not disclosed in this filing.
• Footnote highlights:
  • Lock-Up Agreement (dated Sept 6, 2026): Gallagher agreed not to transfer these shares (or related securities) for 180 days after issuance without the issuer’s written consent.
  • Some securities are held of record by Gallagher as custodian for a minor under UTMA; he disclaims beneficial ownership except to the extent of any pecuniary interest.
  • The warrant was immediately exercisable upon acquisition and was subject to the issuer’s call rights under certain conditions.
• Filing timeliness: report filed with a 2026-09-08 report date; no late filing indicated.

Context

• This was an exercise/conversion of a warrant into common stock (not an open-market purchase or sale). The warrant was surrendered/converted (hence the $0 disposition entry) and replaced by the underlying common shares, which are subject to a 180‑day lock-up. For retail investors, exercises show the insider converted a derivative into stock but do not by themselves indicate intent to hold or sell beyond the lock-up restriction.